0 rating

Rheumatoid Arthritis

van Vollenhoven RF, Emery P, Bingham CO 3rd et al.

Karolinska Institute, Stockholm, Sweden.

 Ann Rheum Dis 2013;72:1496–502.

Ben Parker’s review: The long-term safety of biological therapies in rheumatoid arthritis (RA) is the subject of ongoing investigation. Rituximab is used in the treatment of active RA and has been demonstrated to have a good safety profile in numerous clinical trials. However, the effect of repeated depletion of peripheral B cells on long-term safety in patients with RA has yet to be fully established. In this analysis of long-term outcomes in the global program of clinical trials of rituximab for RA, the authors evaluated the long-term safety data with a specific focus on adverse effects potentially associated with B cell depletion.

Return to top